WO2023107570 - EXPRESSION-WEIGHTED TUMOR MUTATIONAL BURDEN AS AN ONCOLOGY BIOMARKER
National phase entry is expected:
Publication Number
WO/2023/107570
Publication Date
15.06.2023
International Application No.
PCT/US2022/052153
International Filing Date
07.12.2022
Title **
[English]
EXPRESSION-WEIGHTED TUMOR MUTATIONAL BURDEN AS AN ONCOLOGY BIOMARKER
[French]
CHARGE MUTATIONNELLE TUMORALE PONDÉRÉE PAR L'EXPRESSION EN TANT QUE BIOMARQUEUR ONCOLOGIQUE
Applicants **
NUPROBE USA, INC.
Inventors
ZHANG, David Y.
PINTO, Alessandro
WELLER, Cailin B.
THIRUNAVUKARASU, Deepak
Priority Data
63/287,455
08.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2993 | |
| EPO | Filing, Examination, Granting | 25785 | |
| Japan | Filing, Examination, Granting | 3021 | |
| South Korea | Filing, Examination, Granting | 3857 | |
| USA | Filing, Examination, Granting | 8710 |
Total:
44,366
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention discloses methods of calculating an Expression-Weighted Tumor Mutational Burden from a biological sample. RNA is extracted from the biological sample, followed by RNA sequencing and expression-weighted analysis of the RNA sequencing data. The Expression-Weighted Tumor Mutational Burden calculated from these methods can be used in the prognostication of patient outcome and the determination of treatment prescription for patients.[French]
La présente invention concerne des procédés de calcul d'une charge mutationnelle tumorale pondérée par l'expression à partir d'un échantillon biologique. L'ARN est extrait de l'échantillon biologique, suivi du séquençage de l'ARN et de l'analyse pondérée par l'expression des données de séquençage de l'ARN. La charge mutationnelle tumorale pondérée par l'expression calculée à partir de ces procédés peut être utilisée dans le pronostic sur l'évolution de l'état de patients et la détermination d'une prescription de traitement pour des patients.